Phase I Trial of NPI-0052 Begins

Phase I Trial of NPI-0052 Begins

June 1, 2006

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 15 No 6

Volume 15

Issue 6

Nereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.

SAN DIEGO, CalifNereus Pharmaceuticals, Inc. has initiated a phase I trial of its novel, small molecule proteasome inhibitor, NPI-0052, in patients with solid tumors and lymphomas. The trial will enroll approximately 50 patients at two sites, M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center. NPI-0052 was discovered during the fermentation of Salinispora sp, a new class of Gram-positive marine bacteria, Nereus said in a press release.

Articles in this issue

Triple-Negative Cancers More Common in Young Black Pts

Artists Turn Flowers & Curves Into 'Forms' and 'Figures'

Study to Examine Outcomes Disparities in Pediatric ALL

Thalidomide Has 'Changed the Paradigm' in Myeloma Rx

CA4P Gets Orphan Drug Status

Testicular Ca Survivors at Increased Risk for CV Events

A Novel Brings a Cancer Research Laboratory to Life

NCCN Reveals New Venous Thromboembolism Guideline

Lapatinib New Option for Metastatic HER2+ Breast Ca

FDA Approves Dacogen for Treating All MDS Subtypes

Noninvasive Ablation Relieves Chronic Chest Wall Pain

GVAX Receives Fast-Track Status

Medicare CAP Vendor Selected

Selective IGF-1R Inhibitor Blocks Colon Cancer Growth

US Cancer Mortality Drops

Related Content

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024

Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024

Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024

Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024

Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024

Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.